Biotron Ltd (ASX: BIT) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Biotron Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$5.57 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
2.79 billion
Earnings per share
-0.001
Dividend per share
N/A
Year To Date Return
-33.33%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Biotron Ltd (ASX: BIT)
Latest News
Share Gainers
These small cap ASX shares have surged higher on Thursday
Share Fallers
Biotron Limited (ASX:BIT) shares sank 27% lower on Wednesday
Share Fallers
Why these 4 ASX shares have started the week in the red
Share Gainers
The Biotron Limited (ASX:BIT) share price jumped 70% higher this week
Share Gainers
These 3 small cap ASX shares are ending the week on a high
Share Gainers
These 3 ASX shares are pushing higher on Wednesday
Share Gainers
Why these 4 ASX shares have started the week with a bang
Record Highs
The Biotron Limited (ASX:BIT) share price is up 800% in just two weeks
ASX Share Market News
These 3 ASX small cap shares have stormed higher on Thursday
Share Gainers
These 3 small cap ASX shares are posting strong gains on Wednesday
Share Gainers
These 3 small cap ASX shares are on the rise on Tuesday
⏸️ Investing
5 of the best companies presenting at Australia Biotech Invest 2014
BIT ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Biotron Ltd
Biotron Ltd. operates as a clinical stage biotechnology company. It engages in developing and commercializing a novel small molecule approach that treats serious viral disease. The firm's technology targets viroporin proteins, which enables the pathogenicity of a number of viruses including hepatitis C, HIV-1, Dengue, Zika, Influenza and respiratory syncytial virus. Its proprietary bacterial cell-based screening platform enables rapid screening for target viroporin proteins. The company was founded in February 1999 and is headquartered in North Ryde, Australia.
BIT Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | $0.00 | $0.00 | 0.00% | 288,800 | $0.00 | $0.00 | $0.00 |
| 22 Oct 2026 | $0.00 | $0.00 | 0.00% | 1,519 | $0.00 | $0.00 | $0.00 |
| 21 Oct 2026 | $0.00 | $0.00 | 0.00% | 452,016 | $0.00 | $0.00 | $0.00 |
| 20 Oct 2026 | $0.00 | $0.00 | 0.00% | 1,645,167 | $0.00 | $0.00 | $0.00 |
| 19 Oct 2026 | $0.00 | $0.00 | 0.00% | 315,000 | $0.00 | $0.00 | $0.00 |
| 16 Oct 2026 | $0.00 | $0.00 | 0.00% | 11,995,030 | $0.00 | $0.00 | $0.00 |
| 15 Oct 2026 | $0.00 | $0.00 | 0.00% | 4,393,697 | $0.00 | $0.00 | $0.00 |
| 14 Oct 2026 | $0.00 | $0.00 | 0.00% | 4,834,300 | $0.00 | $0.00 | $0.00 |
| 13 Oct 2026 | $0.00 | $0.00 | 0.00% | 10,000 | $0.00 | $0.00 | $0.00 |
| 09 Oct 2026 | $0.00 | $0.00 | 0.00% | 879,814 | $0.00 | $0.00 | $0.00 |
| 08 Oct 2026 | $0.00 | $0.00 | 0.00% | 825,000 | $0.00 | $0.00 | $0.00 |
| 07 Oct 2026 | $0.00 | $0.00 | 0.00% | 6,245,336 | $0.00 | $0.00 | $0.00 |
| 06 Oct 2026 | $0.00 | $0.00 | 0.00% | 1,601,931 | $0.00 | $0.00 | $0.00 |
| 05 Oct 2026 | $0.00 | $0.00 | 0.00% | 2,760,148 | $0.00 | $0.00 | $0.00 |
| 02 Oct 2026 | $0.00 | $0.00 | 0.00% | 1,968 | $0.00 | $0.00 | $0.00 |
| 01 Oct 2026 | $0.00 | $0.00 | 0.00% | 1,598,224 | $0.00 | $0.00 | $0.00 |
| 30 Sep 2026 | $0.00 | $0.00 | 0.00% | 30,155,780 | $0.00 | $0.00 | $0.00 |
| 29 Sep 2026 | $0.00 | $0.00 | 0.00% | 1,968 | $0.00 | $0.00 | $0.00 |
| 28 Sep 2026 | $0.00 | $0.00 | 0.00% | 1,958 | $0.00 | $0.00 | $0.00 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 13 Jul 2026 | Paul Kasian | Exercise | 36,567 | $73 |
Conversion of securities. 36,567 Performance Shares
|
| 13 Jul 2026 | Paul Kasian | Buy | 12,189,000 | $36,567 |
Conversion of securities. Deemed issue price
|
| 13 Jul 2026 | Graeme Wald | Buy | 16,276,333 | $48,828 |
Conversion of securities. Deemed issue price, As per announcement
|
| 13 Jul 2026 | Graeme Wald | Exercise | 48,838 | $97 |
Conversion of securities. 48,838 Performance shares
|
| 19 Dec 2025 | Michael Medway | Issued | 7,500,000 | $22,500 |
Rights issue.
|
| 19 Dec 2025 | Michael Medway | Issued | 15,000,000 | $45,000 |
Rights issue.
|
| 19 Dec 2025 | Michael Hoy | Issued | 7,478,236 | $22,434 |
Rights issue.
|
| 19 Dec 2025 | Michael Hoy | Issued | 3,739,118 | $11,217 |
Rights issue.
|
| 19 Dec 2025 | Robert Thomas | Issued | 2,800,000 | $8,400 |
Rights issue.
|
| 19 Dec 2025 | Robert Thomas | Issued | 1,400,000 | $4,200 |
Rights issue.
|
| 19 Dec 2025 | Michelle Miller | Issued | 1,325,000 | $3,975 |
Rights issue.
|
| 19 Dec 2025 | Michelle Miller | Issued | 1,200,000 | $3,600 |
Rights issue.
|
| 19 Dec 2025 | Michelle Miller | Issued | 1,262,500 | $3,787 |
Rights issue.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr Paul Alexander Kasian | Non-Executive DirectorNon-Executive Chairman | Dec 2025 |
Dr Kasian has 30 years of experience executive and non-executive leadership roles, demonstrating domestic and international success in creating and building businesses. He has experience in business management, organizational development, acquisition integration, financial oversight, capital markets, strengthening board effectiveness, governance and risk management. Dr Kasian is currently Chairman of Diamond Key International.
|
| Dr Michael Joseph Thurn | Non-Executive Director | Oct 2026 |
Dr Thurn is a biotechnology executive and non-executive director with more than 25 years experience spanning drug discovery, preclinical and clinical development, regulatory strategy, capital raising, licensing and company building. He is a former Senior Toxicologist with the Therapeutic Goods Administration and has experience advancing novel therapeutics through development and regulatory pathways. Dr Thurn is currently a Non-Executive Director of Arovella Therapeutics Limited and Erasca Australia Pty Ltd, and a Primary Reviewer with Bellberry Limiteds Human Research Ethics Committee. He was Managing Director and Chief Executive Officer of Neurizon Therapeutics Limited from 2024 to 2026 and has previously held senior executive roles at Botanix Pharmaceuticals, Mimetica, Spinifex Pharmaceuticals, Cytopia Research and Xenome.
|
| Mr Michael James Medway | Non-Executive Director | Jul 2025 |
Mr Medway has worked in the professional accounting industry for over 30 years. He has been a Chartered Accountant for 30 years, and his background has seen him work across various firms in Sydney and Regional NSW, where he provided a range of professional accounting services to a variety of small to medium enterprises. He is currently a Director of Maas Group Holdings Limited (ASX: MGH).
|
| Mr Graeme Wald | Non-Executive Director | Mar 2026 |
Mr Wald is an Industrial Chemist and has worked as a research chemist in South Africa, Israel and the USA. He became an equities analyst. Mr Wald has experience in private equity and venture capital as an Investment Director at BioScience Managers, and a Partner in Fund III at OneVentures. He is CEO and Director of MyrioTherapeutics Pty Ltd, a Melbourne based antibody drug company developing novel antibodies for the treatment of solid tumours and is Chairman of Psaio Therapeutics, also Melbourne based that is developing novel antibodies for the treatment of prostate cancer based on Myrio technology.
|
| Mr Marcelo Mora | Company Secretary | May 2025 |
-
|
| Marcelo Mora | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| 10 Bolivianos Pty Ltd | 263,850,833 | 9.47% |
| Berne No 132 Nominees Pty Ltd <791994 A/C> | 130,228,332 | 4.68% |
| Zebra235 Pty Ltd <Zebra 235 A/C> | 113,955,047 | 4.09% |
| Mgl Corp Pty Ltd | 81,224,854 | 2.92% |
| Rookharp Capital Pty Limited | 75,111,667 | 2.70% |
| Buprestid Pty Ltd <Hanlon Family S/Fund A/C> | 59,558,561 | 2.14% |
| Yongala Investments Pty Ltd <Yongala Family A/C> | 49,085,487 | 1.76% |
| Riya Investments Pty Ltd | 42,333,333 | 1.52% |
| Cowen Investments Junior Pty Ltd <Juttacowen A/C> | 42,035,045 | 1.51% |
| Jey Investment Pty Ltd | 39,028,317 | 1.40% |
| Yongala Investments Pty Ltd <Kasian Super Fund A/C> | 36,237,051 | 1.30% |
| Mr Troy Harris | 35,000,000 | 1.26% |
| Citicorp Nominees Pty Limited | 34,913,658 | 1.25% |
| 3M Holdings Pty Limited <3M Investment Spec A/C> | 33,999,671 | 1.22% |
| Emnj Pty Ltd <Lamorran Super Fund A/C> | 32,613,346 | 1.17% |
| Mrs Hyun Kyung Kim | 32,000,000 | 1.15% |
| Mandeville Property Group Pty Ltd <Harris Sf A/C> | 31,500,000 | 1.13% |
| Umbiram Pty Ltd <Michael Hoy Superfund A/C> | 29,912,941 | 1.07% |
| Bilgola Nominees Pty Limited | 26,076,103 | 0.94% |
| Mr Biao Mu | 23,903,778 | 0.86% |
